{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T16:53:09Z","timestamp":1788713589052,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess if sodium\u2010glucose co\u2010transporter\u20102 inhibitors (SGLT2is) reduce the risk of all\u2010cause mortality, cardiovascular death and hospitalization for heart failure (HF) or chronic kidney disease (CKD) to a greater extent than dipeptidyl peptidase\u20104 inhibitors (DPP4is) in people with type 2 diabetes (T2D) with or without established cardiovascular and\/or renal disease (CVRD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study propensity\u2010matched 24\u2009438 patients receiving an SGLT2i 1:1 to a patient receiving a DDP4i, stratified based on the presence of CVRD. The primary outcomes were the time to each of the following: all\u2010cause mortality, cardiovascular death or hospitalization for HF, myocardial infarction, stroke and CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, SGLT2is were associated with reductions in all\u2010cause mortality, cardiovascular mortality, hospitalization for HF and hospitalization for CKD compared with DPP4is. In patients with no CVRD history, SGLT2is were associated with reductions in all\u2010cause mortality (HR 0.71, 95% CI 0.57\u20100.88;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a0.002), hospitalization for HF (HR 0.76, 95% CI 0.59\u20100.98;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a0.035) and hospitalization for CKD (HR 0.75, 95% CI 0.63\u20100.88;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001). In patients with established cardiovascular disease (CVD) or at high risk, SGLT2is were associated with reductions in all\u2010cause mortality (HR 0.69, 95% CI 0.59\u20100.82;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001), cardiovascular mortality (HR 0.76, 95% CI 0.62\u20100.95;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a0.014), hospitalization for HF (HR 0.73, 95% CI 0.63\u20100.85;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001), hospitalization for stroke (HR 0.75, 95% CI 0.59\u20100.94;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a0.013) and hospitalization for CKD (HR 0.49, 95% CI 0.43\u20100.54;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There was consistency across subgroups and sensitivity analyses. SGLT2is were associated with a reduced risk of all\u2010cause mortality and hospitalization for HF and CKD compared with DPP4\u2010is, highlighting the need to introduce SGLT2is early in the management of patients with T2D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14437","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T12:39:51Z","timestamp":1620736791000},"page":"2207-2214","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Lower risk of hospitalization for heart failure, kidney disease and death with sodium\u2010glucose co\u2010transporter\u20102 inhibitors compared with dipeptidyl peptidase\u20104 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care"],"prefix":"10.1111","volume":"23","author":[{"given":"Iskandar","family":"Idris","sequence":"first","affiliation":[{"name":"Division of Medical Sciences and Graduate Entry Medicine, School of Medicine University of Nottingham, Royal Derby Hospital  Derby UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Robertson Centre for Biostatistics, Institute of Health and Wellbeing University of Glasgow  Glasgow UK"},{"name":"Medical and Scientific Affairs BioPharmaceuticals Medical, AstraZeneca  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jil Billy","family":"Mamza","sequence":"additional","affiliation":[{"name":"Medical and Scientific Affairs BioPharmaceuticals Medical, AstraZeneca  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Ford","sequence":"additional","affiliation":[{"name":"Medical and Scientific Affairs BioPharmaceuticals Medical, AstraZeneca  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamsin","family":"Morris","sequence":"additional","affiliation":[{"name":"Medical and Scientific Affairs BioPharmaceuticals Medical, AstraZeneca  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitava","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Institute of Health Informatics University College  London UK"},{"name":"Department of Cardiology University College London Hospitals  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2343-7099","authenticated-orcid":false,"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre University of Leicester  Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.8.1879"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000377"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.3.612"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2019.07.003"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l223"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.08.020"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14074"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa183"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30258-9"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30384-5"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.03.009"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038868"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.029190"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14189"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13830"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/psb.1626"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5135"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.047480"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0074"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-10024-2"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30130-3"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3342"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14437","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14437","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:34:18Z","timestamp":1761885258000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/dom.14437"],"URL":"https:\/\/doi.org\/10.1111\/dom.14437","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.14437\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14437\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14437\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14437\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14437\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14437\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14437\/v2\/response1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]},"assertion":[{"value":"2021-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}